ABSTRACT Background/Aims: We aimed to evaluate the impact of non-alcoholic fatty liver
disease (NAFLD) on viral kinetics and virologic response to tenofovir and entecavir …

Background & aims Nonalcoholic fatty liver disease (NAFLD) and chronic hepatitis B (CHB)
are common liver diseases. Concurrent NAFLD may affect antiviral treatment outcomes in …

BACKGROUND Tenofovir alafenamide (TAF) has a serum lipid-raising effect in patients with
HIV; however, its effect on serum lipids and nonalcoholic fatty liver disease (NAFLD) risk in …

Background/Aims The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is
unclear. We evaluated the influence of the degree of HS, assessed using the controlled …

Background The coexistence of HBV infection and nonalcoholic fatty liver disease (NAFLD)
becomes characteristic of liver disease in China, with unknown bilateral influence. We …

Background/Aims Tenofovir alafenamide (TAF) has shown less favorable effect on lipids
compared to tenofovir disoproxil fumarate (TDF) in clinical trials. However, data regarding …

Background Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are first‐line
treatments for chronic hepatitis B (CHB). Studies suggest lipid lowering effect of TDF in …

The impact of long‐term nucleos (t) ide analogs treatment on host metabolism is a concern.
Hence, we conducted this study to compare the effect of entecavir (ETV) and tenofovir …

Background Tenofovir alafenamide (TAF) is a new anti-hepatitis B virus nucleotide analogue
that can cause dyslipidaemia in AIDS patients, but the effect of TAF on blood lipids in …

Background Lipid‐lowering effect was observed during treatment with tenofovir disoproxil
fumarate (TDF) for chronic hepatitis B (CHB). However, the metabolic features in patients …